<div>
                                <figure class="article-image__container">
                                    
                                    
                                    
                                    <img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-2-10-04-2026-shutterstock_2006854028-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-2-10-04-2026-shutterstock_2006854028-430x241.jpg"/>
                                    
                                    <figcaption>Roche will manage antibody selection, conjugation, preclinical and clinical development, and commercialisation. Credit: Melnikov Dmitriy / Shutterstock.com.</figcaption>
                                </figure>
                            </div>
                                        
<p>Roche has signed a new collaboration agreement with C4 Therapeutics to jointly advance research in the field of degrader-antibody conjugates (DACs), aiming to introduce a new therapeutic modality for cancer.</p>



<p>According to the joint research plan, the companies will partner on two programmes for developing DACs against undisclosed oncology targets.</p><div>
<div id="div-gpt-ad-6065588-4"></div>
  
</div><div><div>
                   <div><h3>Go deeper with GlobalData</h3><ul><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>LOA and PTSR Model - Monoclonal Antibody Conjugate 3 To Target Egfr... </h4></div> </li><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>LOA and PTSR Model - Monoclonal Antibody Conjugate 3 To Target Egfr... </h4></div> </li></ul> <div>
                    <h5>
                                                Go deeper with GlobalData
                                            </h5>
                    <p>
                        The gold standard of business intelligence.
                    </p>
                    <p>
                            Find out more
                            
                                
                            
                        
                    </p>
                </div>
                </div></div><section><figure><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></figure><h4> Discover B2B Marketing That Performs </h4><p>
						Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
					</p><p>
							Find out more </p></section></div>



<p>C4 Therapeutics will use its TORPEDO platform for degrader payload design while Roche will manage antibody selection, conjugation, preclinical and clinical development, and commercialisation.</p><div id="slot-one"></div><div id="Sgpollsputhere"></div>



<p>C4 Therapeutics will receive a $20m upfront payment and additional discovery milestone payments, with potential to earn more than $1bn in regulatory and commercial milestones, plus tiered royalties on future sales.</p>



<p>C4 Therapeutics president and CEO Andrew Hirsch said: “For the past decade, C4T and Roche have worked together to drive research in targeted protein degradation and to establish this modality as a new way to treat cancer.</p>



<p>“Our new collaboration leverages C4T’s ability to design highly catalytic and selective degraders, as well as degrader payloads for DACs, alongside Roche’s extensive experience developing ADCs with specific binding.”</p>



<p>“Together, these capabilities build a powerful new modality that can offer transformative medicines for patients.”</p>



<p>Roche corporate business development head Boris Zaïtra said: “Roche has been a believer in targeted protein degradation and its potential for differentiation early on, when partnering with C4T for the first time in 2016.</p><div id="slot-two"></div>



<p>“Our relationship with C4 Therapeutics is built on a decade of trust and shared scientific ambition. We are pleased to enter into our third collaboration, expanding our long-standing partnership to pioneer the emerging modality of DACs.”</p>



<p>In February 2026, Roche obtained acceptance from the US Food and Drug Administration for its new drug application submitted for the giredestrant oral therapy, along with everolimus, to treat breast cancer.</p>
<div id="slot-three"></div><p></p>



<div>
    
</div>

CCCC

<p>Roche has entered a collaboration with C4 Therapeutics to advance research on degrader-antibody conjugates (DACs) for cancer treatment. Roche will oversee antibody selection, development, and commercialization, while C4 Therapeutics will utilize its TORPEDO platform for payload design. The deal includes a $20 million upfront payment and potential earnings exceeding $1 billion in milestones and royalties. This partnership builds on a decade of collaboration aimed at pioneering new therapeutic modalities for cancer.</p>

Roche and C4 Therapeutics to advance degrader-antibody conjugates research